Epic Sciences Announces Completion of New York State Licensure to Provide the Oncotype DX AR-V7 Nucleus Detect Test for Patients with Metastatic Castration-Resistant Prostate Cancer in New York State
SAN DIEGO, Calif., March 20, 2019 -- Epic Sciences, Inc. (Epic) announced today that the New York State Department of Health has completed licensure to provide the Oncotype DX® AR-V7 Nucleus Detect™ test for patients with metastatic castration-resistant prostate cancer (mCRPC).
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
New data from the PROPHECY trial, published in the Journal of Clinical Oncology, demonstrate that detection of AR-V7 in circulating tumor cells (CTCs) in blood is predictive of whether men with mCRPC have become resistant to androgen-receptor signaling (ARS) inhibitors and have a low chance of benefit from further ARS therapy.
Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development
Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-16, 2019.
Epic Sciences to Present Data at SABCS 2018
Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 - 8 in San Antonio, TX.
Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer
Epic Sciences is collaborating with four major breast cancer centers on a clinical trial to determine if Epic’s blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer.
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer, Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage.
Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies
Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated.